Dogecoin Cash, Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 12, 2025 and accepted by EDGAR at Nov 12, 2025, 11:18 ET.
Management's discussion and analysis
As filed, 6,363 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Results of Operations
Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024
| 2025 | Three Months Ended A September 30, 2024 | B September 30, | A-B Change | Change % |
|---|---|---|---|---|
| REVENUE | $190,564 | $189,121 | $1,443 | 1% |
| Cost of revenues | 68,615 | 70,249 | (1,634) | (2)% |
| Cost of sales % of total sales | 36% | 37% | (1)% | (3)% |
| Gross profit | 121,949 | 118,872 | 3,077 | 3% |
| Gross profit % of sales | 64% | 63% | ||
| EXPENSES | ||||
| Professional fees | 70,309 | 114,456 | (44,147) | (39)% |
| Depreciation and amortization | 301 | 301 | –– | ––% |
| Wages and salaries | 77,878 | 82,293 | (4,415) | (5)% |
| Advertising | 394 | 996 | (602) | (60)% |
| General and administrative | 120,236 | 102,673 | 17,563 | 17% |
| Total expenses | 269,118 | 300,719 | (31,601) | (11)% |
| NET LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS | (147,169) | (181,847) | 34,678 | (19)% |
Revenue for the three months ended September 30, 2025, increased 1% compared to the three months ended September 30, 2024. Cost of revenues as a percentage of sales decreased 2% between the periods. The increase in revenues was primarily attributable to a modest uptick in patient certifications through PrestoDoctor, driven by recent state-market expansions, new referral arrangements with retailers, and enhanced marketing initiatives. The demand for our services remained relatively consistent during the three months ended September 30, 2025, with revenues reflecting stable patient activity levels.
Nine Months Ended September 30, 2025 compared with the Nine Months Ended September 30, 2024
| 2025 | Nine Months Ended A September 30, 2024 | B September 30, | A-B Change | Change % |
|---|---|---|---|---|
| REVENUE | $567,501 | $648,643 | $(81,142) | (13)% |
| Cost of revenues | 207,109 | 253,369 | (46,260) | (18)% |
| Cost of sales % of total sales | 36% | 39% | (3)% | (7)% |
| Gross profit | 360,392 | 395,274 | (34,882) | (9)% |
| Gross profit % of sales | 64% | 61% | ||
| EXPENSES | ||||
| Professional fees | 149,221 | 263,690 | (114,469) | (43)% |
| Depreciation and amortization | 904 | 3,028 | (2,124) | (70)% |
| Wages and salaries | 227,295 | 293,373 | (66,078) | (23)% |
| Advertising | 2,893 | 8,928 | (6,035) | (68)% |
| General and administrative | 412,278 | 380,838 | 31,440 | 8% |
| Total expenses | 792,591 | 949,857 | (157,266) | (17)% |
| NET LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS | (432,199) | (554,583) | 122,384 | (22)% |
Revenue for the nine months ended September 30, 2025, decreased 13% compared to the nine months ended September 30, 2024. Cost of revenues as a percentage of sales decreased 18% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2025.
Total operating expenses decreased in September 30, 2025 compared with 2024 which trended down as did revenue in the current period. Decreases in professional fees, depreciation & amortization, wages and salaries, and advertising expenses. PrestoDoctor management salaries also decreased during the nine months ended September 30, 2025. PrestoDoctor wages and salaries decreased approximately $66,000, or 23%, to $227,295 for the nine months ended September 30, 2025, compared with $293,373 for the nine months ended September 30, 2024. The decrease primarily reflects lower staffing levels and continued cost-management efforts at PrestoDoctor, while management compensation remained generally consistent period over period.
Liquidity and Capital Resources
Cash used in operating activities was $36,658 in the nine months ended September 30, 2025. We ended the third quarter of 2025 with $29,978 in cash on hand.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $7,581,141 and $854,454, respectively, for the nine months ended September 30, 2025 and 2024 and had an accumulated deficit of $84,305,776 as of September 30, 2025. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
The amount of cash on hand the Company has does not provide sufficient liquidity to meet the immediate needs of our current operations.
Off Balance Sheet Arrangements
None
Controls and procedures
As filed, 1,829 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures
At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.
Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting during the quarter ended September 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $190.6k | us-gaap:Revenues |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $567.5k | us-gaap:Revenues |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $68.6k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $207.1k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $121.9k | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $360.4k | us-gaap:GrossProfit |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$147.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$432.2k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-07-01 to 2025-09-30 | $57.9k | us-gaap:InterestExpense |
| Interest expense | 9 months2025-01-01 to 2025-09-30 | $79.5k | us-gaap:InterestExpense |
| Income tax | 3 months2025-07-01 to 2025-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$178.4k | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$7.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | −$36.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-09-30 | $30.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $780.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $2.1m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $797.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $2.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-09-30 | −$1.8m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-09-30 | 160,109,031 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001096906-25-001794. Last ingested by Listed: Nov 3, 2026, 21:17 ET. Listed shows no prices and gives no investment advice.